Ralliant Corporation (NYSE:RAL) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Ralliant Corporation (NYSE:RAL) have received an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $67.30.

A number of analysts have recently weighed in on the stock. Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target for the company. in a report on Wednesday, May 27th. Royal Bank Of Canada upped their price target on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded shares of Ralliant from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Truist Financial reaffirmed a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Finally, Evercore assumed coverage on shares of Ralliant in a report on Tuesday. They set an “outperform” rating and a $80.00 price target for the company.

Ralliant Stock Performance

NYSE RAL opened at $65.66 on Friday. The firm has a 50-day moving average price of $52.57 and a two-hundred day moving average price of $49.71. Ralliant has a 12-month low of $37.27 and a 12-month high of $65.91. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $7.35 billion and a P/E ratio of -6.00.

Ralliant (NYSE:RAL) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company had revenue of $534.60 million during the quarter. The firm’s revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Analysts anticipate that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

Hedge Funds Weigh In On Ralliant

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Ralliant by 10.7% during the 3rd quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after purchasing an additional 1,415,327 shares in the last quarter. Dodge & Cox increased its position in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after purchasing an additional 1,434,376 shares in the last quarter. Viking Global Investors LP acquired a new position in Ralliant during the 2nd quarter worth approximately $257,200,000. Millennium Management LLC increased its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after purchasing an additional 3,147,660 shares in the last quarter. Finally, State Street Corp acquired a new position in Ralliant during the 2nd quarter worth approximately $213,096,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.